Understanding how ovarian cancer becomes resistant to a specific treatment.
NAD+ metabolism in PARP inhibitor resistance of ovarian cancer
This study is looking into why some patients with high-grade serous ovarian cancer don’t respond to a certain treatment called PARP inhibitors, focusing on a specific enzyme that helps cancer cells fix themselves, with the hope of finding better treatment options for those who need them.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11067797 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind why high-grade serous ovarian cancer (HGSOC) becomes resistant to PARP inhibitors, a treatment that is effective for some patients with BRCA1 or BRCA2 mutations. The study focuses on the role of a specific enzyme, NMNAT1, which is linked to increased levels of NAD+, a molecule that helps cancer cells repair themselves. By using cell lines and patient-derived models, the researchers aim to identify potential new treatment strategies that could target this resistance mechanism. Patients may benefit from insights that could lead to more effective therapies for recurrent ovarian cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with high-grade serous ovarian cancer, particularly those with BRCA1 or BRCA2 mutations who have experienced treatment resistance.
Not a fit: Patients with ovarian cancer types that do not involve BRCA mutations or those who have not developed resistance to current therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with ovarian cancer who currently have limited effective therapies.
How similar studies have performed: Previous research has shown promising results in understanding cancer treatment resistance, but this specific approach focusing on NMNAT1 and NAD+ metabolism is relatively novel.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Kanakkanthara, Arun — Mayo Clinic Rochester
- Study coordinator: Kanakkanthara, Arun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.